{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:05:35Z","timestamp":1783062335735,"version":"3.54.6"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002203","name":"The Brain Tumour Charity","doi-asserted-by":"publisher","award":["CB_2019\/1_10398"],"award-info":[{"award-number":["CB_2019\/1_10398"]}],"id":[{"id":"10.13039\/501100002203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002203","name":"The Brain Tumour Charity","doi-asserted-by":"publisher","award":["GN-000682"],"award-info":[{"award-number":["GN-000682"]}],"id":[{"id":"10.13039\/501100002203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","award":["KFS-5555-02-2022"],"award-info":[{"award-number":["KFS-5555-02-2022"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["320030_215718"],"award-info":[{"award-number":["320030_215718"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203312"],"award-info":[{"award-number":["NIHR203312"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Diffuse IDH mutant low-grade gliomas (IDHmt\u00a0LGG) (World Health Organization grade 2) typically affect young adults. The outcome is variable, with survival ranging from 5 to over 20 years. The timing and choice of initial treatments after surgery remain controversial. In particular, radiotherapy is associated with early and late cognitive toxicity. Over 90% of\u00a0IDHmt\u00a0LGG exhibit some degree of promoter methylation of the repair gene O(6)-methylguanine-DNA methytransferase (MGMTp) that when expressed blunts the effect of alkylating agent chemotherapy, for example, temozolomide (TMZ). However, the clinical value of MGMTp methylation predicting benefit from TMZ in IDHmt\u00a0LGG is unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients treated in the EORTC-22033 phase III trial comparing TMZ versus radiotherapy served as training set to establish a cutoff based on the MGMT-STP27 methylation score. A validation cohort was established with patients treated in a single-center first-line with\u00a0TMZ after surgery\/surgeries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The MGMT-STP27 methylation score was associated with better progression-free survival (PFS) in the training cohort treated with TMZ, but not radiotherapy. In the validation cohort, an association with next treatment-free survival (P\u2005=\u2005.045) after TMZ was observed, and a trend using RANO criteria (P\u2005=\u2005.07). A cutoff value set above the 95% confidence interval of being methylated was significantly associated with PFS in the TMZ-treated training cohort, but not in the radiotherapy arm. However, this cutoff could not be confirmed in the test cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While the MGMTp methylation score was associated with better outcomes in TMZ-treated IDHmt LGG, a cutoff could not be established to guide treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdae224","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:58:36Z","timestamp":1734598716000},"source":"Crossref","is-referenced-by-count":5,"title":["Clinical value of the <i>MGMT<\/i> promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment"],"prefix":"10.1093","volume":"7","author":[{"given":"Am\u00e9lie","family":"Darlix","sequence":"first","affiliation":[{"name":"Institute of Functional Genomics IGF, University of Montpellier, CNRS, INSERM , Montpellier,","place":["France"]},{"name":"Department of Medical Oncology, Institut R\u00e9gional du Cancer de Montpellier, University of Montpellier , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1398-4689","authenticated-orcid":false,"given":"Pierre","family":"Bady","sequence":"additional","affiliation":[{"name":"SIB Swiss Institute of Bioinformatics , Lausanne,","place":["Switzerland"]},{"name":"Translational Data Science & Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne , Lausanne,","place":["Switzerland"]},{"name":"Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne , Lausanne,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Deverdun","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier,","place":["France"]},{"name":"Department of Neuroradiology, I2FH, Institut d\u2019Imagerie Fonctionnelle Humaine, Montpellier University Medical Center , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lefort","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne , Lausanne,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-5489","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Rigau","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier,","place":["France"]},{"name":"Institute of Functional Genomics IGF, University of Montpellier, CNRS, INSERM , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Le Bars","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier,","place":["France"]},{"name":"Department of Neuroradiology, I2FH, Institut d\u2019Imagerie Fonctionnelle Humaine, Montpellier University Medical Center , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-9868","authenticated-orcid":false,"given":"Justine","family":"Meriadec","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Carri\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Coget","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Santarius","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-5715","authenticated-orcid":false,"given":"Tomasz","family":"Matys","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-2342","authenticated-orcid":false,"given":"Hugues","family":"Duffau","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center , Montpellier,","place":["France"]},{"name":"Institute of Functional Genomics IGF, University of Montpellier, CNRS, INSERM , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-6495","authenticated-orcid":false,"given":"Monika E","family":"Hegi","sequence":"additional","affiliation":[{"name":"Departments of Oncology and Clinical Neurosciences, L. Lundin and Family Brain Tumor Research Center, Lausanne University Hospital and University of Lausanne , Lausanne,","place":["Switzerland"]},{"name":"Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne , Lausanne,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"6","key":"2025030501421975400_CIT0001","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"2025030501421975400_CIT0002","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.lanepe.2024.101078","article-title":"Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort study","volume":"46","author":"Ng","year":"2024","journal-title":"Lancet Reg Health Eur."},{"issue":"14","key":"2025030501421975400_CIT0003","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med."},{"issue":"11","key":"2025030501421975400_CIT0004","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.21.02929","article-title":"Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma","volume":"41","author":"Hervey-Jumper","year":"2023","journal-title":"J Clin Oncol."},{"issue":"8","key":"2025030501421975400_CIT0005","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","article-title":"Surgical resection versus watchful waiting in low-grade gliomas","volume":"28","author":"Jakola","year":"2017","journal-title":"Ann Oncol."},{"key":"2025030501421975400_CIT0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2017.12.008","article-title":"An attempt to conceptualize the individual onco-functional balance: why a standardized treatment is an illusion for diffuse low-grade glioma patients","volume":"122","author":"Mandonnet","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"issue":"2","key":"2025030501421975400_CIT0007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/neuonc\/now275","article-title":"Controversies in management of low-grade gliomas in light of new data from clinical trials","volume":"19","author":"Ruda","year":"2017","journal-title":"Neuro Oncol"},{"issue":"7","key":"2025030501421975400_CIT0008","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/neuonc\/noz033","article-title":"Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of","volume":"21","author":"Schiff","year":"2019","journal-title":"Neuro Oncol"},{"issue":"6","key":"2025030501421975400_CIT0009","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"2025030501421975400_CIT0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med."},{"issue":"7","key":"2025030501421975400_CIT0011","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMe2305639","article-title":"Headway against brain tumors with molecular targeting of IDH-mutant gliomas","volume":"389","author":"Schiff","year":"2023","journal-title":"N Engl J Med."},{"issue":"11","key":"2025030501421975400_CIT0012","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"2025030501421975400_CIT0013","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"Lancet Neurol."},{"issue":"9490","key":"2025030501421975400_CIT0014","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"van den Bent","year":"2005","journal-title":"Lancet."},{"issue":"4","key":"2025030501421975400_CIT0015","first-page":"264","article-title":"Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network","volume":"6","author":"Darlix","year":"2019","journal-title":"Neurooncol. Pract.."},{"issue":"10","key":"2025030501421975400_CIT0016","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"11","key":"2025030501421975400_CIT0017","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/neuonc\/nov198","article-title":"Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma","volume":"17","author":"Hegi","year":"2015","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025030501421975400_CIT0018","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jmoldx.2015.11.009","article-title":"Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors","volume":"18","author":"Bady","year":"2016","journal-title":"J Mol Diagn."},{"issue":"4","key":"2025030501421975400_CIT0019","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00401-018-1810-6","article-title":"The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033","volume":"135","author":"Bady","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"21","key":"2025030501421975400_CIT0020","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2025030501421975400_CIT0021","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00401-012-1016-2","article-title":"MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status","volume":"124","author":"Bady","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2025030501421975400_CIT0022","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0197-2456(00)00104-5","article-title":"Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates","volume":"21","author":"Hsieh","year":"2000","journal-title":"Control Clin Trials."},{"issue":"26","key":"2025030501421975400_CIT0023","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2025030501421975400_CIT0024","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00401-014-1315-x","article-title":"Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma","volume":"128","author":"Wiestler","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2025030501421975400_CIT0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s13059-014-0503-2","article-title":"Functional normalization of 450k methylation array data improves replication in large cancer studies","volume":"15","author":"Fortin","year":"2014","journal-title":"Genome Biol."},{"key":"2025030501421975400_CIT0026","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/1471-2105-11-587","article-title":"Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis","volume":"11","author":"Du","year":"2010","journal-title":"BMC Bioinf."},{"issue":"1","key":"2025030501421975400_CIT0027","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"issue":"1","key":"2025030501421975400_CIT0028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2018.02.003","article-title":"InfiniumPurify: an R package for estimating and accounting for tumor purity in cancer methylation research","volume":"5","author":"Qin","year":"2018","journal-title":"Genes Dis"},{"issue":"1","key":"2025030501421975400_CIT0029","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-9473(94)90135-X","article-title":"Multiple factor analysis (AFMULT package)","volume":"18","author":"Escofier","year":"1994","journal-title":"Comput Stat Data Anal"},{"issue":"3","key":"2025030501421975400_CIT0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/03610919808813512","article-title":"A permutation test of association between configurations by means of the rv coefficient","volume":"27","author":"Heo","year":"1998","journal-title":"Commun Stat Simul Comput."},{"issue":"1","key":"2025030501421975400_CIT0031","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1038\/s41467-022-31827-x","article-title":"DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun."},{"key":"2025030501421975400_CIT0032","doi-asserted-by":"crossref","DOI":"10.1201\/9781003277965","volume-title":"Model-Based Clustering, Classification and Density Estimation Using Mclust in R","author":"Scrucca","year":"2023"},{"key":"2025030501421975400_CIT0033","volume-title":"Extending Linear Models with R: Generalized Linear, Mixed Effects and Nonparametric Regression Models","author":"Faraway","year":"2006"},{"issue":"38","key":"2025030501421975400_CIT0034","doi-asserted-by":"crossref","first-page":"61916","DOI":"10.18632\/oncotarget.11322","article-title":"Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial","volume":"7","author":"Quillien","year":"2016","journal-title":"Oncotarget"},{"key":"2025030501421975400_CIT0035","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"issue":"7697","key":"2025030501421975400_CIT0036","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature."},{"issue":"11","key":"2025030501421975400_CIT0037","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/neuonc\/noaa059","article-title":"MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence","volume":"22","author":"Mathur","year":"2020","journal-title":"Neuro Oncol"},{"issue":"7804","key":"2025030501421975400_CIT0038","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature."},{"issue":"12","key":"2025030501421975400_CIT0039","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/neuonc\/noae157","article-title":"MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma","volume":"26","author":"Lim-Fat","year":"2024","journal-title":"Neuro Oncol."},{"issue":"10","key":"2025030501421975400_CIT0040","first-page":"608","article-title":"Glioma CpG Island Methylator Phenotype (G-CIMP): biological and clinical implications","volume":"20","author":"Malta","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025030501421975400_CIT0041","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdae224\/61233941\/vdae224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdae224\/61233941\/vdae224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdae224\/61233941\/vdae224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T01:42:47Z","timestamp":1741138967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdae224\/7928331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdae224","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,19]]},"article-number":"vdae224"}}